Wang Xinxin, Cao Yanli
Department of Endocrinology and Metabolism, Institute of Endocrinology, NHC Key Laboratory of Diagnosis and Treatment of Thyroid Diseases, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
Biomolecules. 2025 Jan 28;15(2):188. doi: 10.3390/biom15020188.
A growing body of evidence emphasizes the role of glycemic variability (GV) in the development of conventional diabetes-related complications. Furthermore, advancements in diabetes management and increased life expectancy have led to the emergence of new complications, such as cancer, liver disease, fractures, infections, and cognitive dysfunction. GV is considered to exacerbate oxidative stress and inflammation, acting as a major mechanism underlying these complications. However, few reviews have synthesized the association between GV and these emerging complications or examined their underlying mechanisms. Hence, this narrative review provides a comprehensive discussion of the burden, risks, and mechanisms of GV in these complications, offering further evidence supporting GV as a potential therapeutic target for diabetes management.
越来越多的证据强调血糖变异性（GV）在传统糖尿病相关并发症发生发展中的作用。此外，糖尿病管理的进展和预期寿命的延长导致了新并发症的出现，如癌症、肝脏疾病、骨折、感染和认知功能障碍。GV被认为会加剧氧化应激和炎症，是这些并发症的主要潜在机制。然而，很少有综述综合阐述GV与这些新出现并发症之间的关联或研究其潜在机制。因此，本叙述性综述全面讨论了GV在这些并发症中的负担、风险和机制，提供了进一步的证据支持将GV作为糖尿病管理的潜在治疗靶点。
